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Malignancies
Dustin A. Silverman, Ross Wanner, Patrick Walz, 
Matthew O. Old and Kris R. Jatana
Abstract
Head and neck malignancies are a part of the differential diagnosis of head and 
neck masses seen in the pediatric age group. It is critical to make prompt diagnosis 
and employ proper treatment. We will review the most common malignant patholo-
gies as well as their specific clinical presentations and management. Centers that 
are able to provide multidisciplinary care for pediatric patients with head and neck 
pathology can help achieve the best outcomes.
Keywords: pediatric tumor, malignancy, neck mass, pediatric cancer,  
head and neck cancer
1. Introduction
Head and neck malignancies are rare within the pediatric population and 
represent 12% of all pediatric cancers according to the National Cancer Institute’s 
Surveillance, Epidemiology, and End Results (SEER) database [1]. While epithe-
lial tumors are more common in adults, childhood tumors are more frequently 
derived from mesenchymal and endothelial cells. Genetic conditions, previous 
chemotherapy, or exposure to ionizing radiation predispose this population to both 
primary and secondary malignancies, but the cumulative environmental carcinogen 
exposures (e.g. cigarette smoke inhalation, ultraviolet radiation) are much less com-
mon given the patients’ younger ages [2].
The most common pediatric head and neck cancers include lymphoma (Hodgkin 
and non-Hodgkin), rhabdomyosarcoma, thyroid carcinoma, nasopharyngeal carci-
noma, and salivary gland malignancies (Figure 1). While other malignancies such 
as neuroblastoma, neuroendocrine tumors, various soft-tissue sarcomas, cutaneous 
tumors, and metastases infrequently manifest within the head and neck region, 
a complete and thorough discussion of these cancers is outside the scope of this 
review and are covered elsewhere throughout literature. The primary aim of this 
review is to highlight the more common head and neck childhood malignancies and 
present a focused examination of the etiology, presentation, workup, and treatment 
of these conditions.
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2. Lymphomas
Lymphoma is the third most common pediatric malignancy - following leukemia 
and brain tumors - and the most common head and neck cancer in children and 
adolescents [3]. The broad differential diagnosis for small round blue cell tumors, 
like lymphoma is shown in Table 1. The treatment of childhood lymphoma has 
experienced significant improvements in recent decades and is now associated with 
cure rates approaching 80 to 90% [4, 5]. Lymphoma is divided into two groups: 
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). HL is further 
subdivided into two clinical subtypes by the World Health Organization (WHO) 
classification which includes classic Hodgkin lymphoma (CHL), which accounts 
for approximately 95% of HL cases within the United States, and nodular lym-
phocyte-predominant Hodgkin lymphoma (NLPHL). Overall, HL is less common 
Figure 1. 
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Differential diagnosis of small round blue cell tumors.
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in developed countries with distribution patterns that vary widely according to 
geography and ethnicity. HL is characterized by a bimodal distribution with a peak 
in adolescence between 15 and 40 years of age and another in adulthood beyond 
60 years of age. Recently, HL has been shown to cluster within certain families with 
associations to specific HLA loci, thus suggesting vertical transmission of suscep-
tible genotypes [6]. Pediatric HL exhibits a 2:1 male predominance with as many as 
40 to 50% of cases linked to the Epstein Barr virus (EBV) infection as well as the 
pathognomonic Reed-Sternberg cell morphology [7–9]. Four subtypes of HL have 
been characterized: nodular sclerosis, mixed cellularity, lymphocyte predominant, 
and lymphocyte depleted, which account for roughly 50%, 30%, 15%, and less than 
10% of the cases, respectively [10]. The Ann Arbor staging system is used to stratify 
these tumors based on the extent of disease and whether organs on one or both sides 
of the diaphragm are involved (Table 2).
In contrast to HL, the incidence of pediatric NHL is lower in younger children 
and increases with age. Pediatric NHL is more frequently associated with higher 
grades and extranodal involvement when compared to cases of adult NHL. 
Average survival rates are greater than 80%, regardless of histologic subtype, of 
which there are several [4]. The most common pediatric NHL subtype is Burkitt 
lymphoma (BL) which accounts for 50 to 60% of childhood cases, followed 
by T-cell lymphoblastic lymphoma (1520%), anaplastic large cell lymphoma 
(1015%), diffuse large B-cell lymphoma (510%), followed by other rare subtypes 
[11]. BL, a highly aggressive tumor, is derived from the classic t(8;14) cytogenetic 
translocation of the MYC oncogene resulting in a constitutive overexpression 
of c-myc leading to rapid cell division [12, 13]. EBV is a well-known endemic 
oncogenic driver and is most prevalent in regions such as Africa where malaria 
continues to thrive. Young patients often present with the characteristic man-
dibular tumor with extranodal and multifocal involvement (in gastrointestinal, 
hematologic, breast, and ovarian tissues) [14]. Compared to endemic BL, its 
sporadic form is more common in non-endemic regions such as the United States 
and Europe [15]. Sporadic form patients are more likely to be male and older 
(median age 30 years old) with localized lymphadenopathy, large abdominal 
masses, extranodal disease (2385%), central nervous system involvement (10%), 
and bone marrow manifestations (13–40%) [16, 17]. Moreover, children with 
Stage Description
I Involvement of a single lymph node region (cervical, axillary, inguinal, mediastinal) or lymphoid 
structure (spleen, thymus, or Waldeyer’s ring) (I); or extralymphatic site in the absence of involved 
nodes (I-E)
II Two or more sites on the same side of the diaphragm (II) including:
• Two or more lymph node regions
• Regional lymph nodes with associated local lymphoid structure involvement
• Extralymphatic site with regional node involvement (II-E)
III Involvement of regional lymph nodes or lymphoid structures on both sides of the diaphragm (III):
• With or without extension to extralymphatic tissue (III-E), the spleen (III-S), or both (III-E,S)
IV Diffuse or disseminated involvement (IV) of:
• One or more extralymphatic organs with or without associated lymph node involvement
• Non-contiguous extralymphatic involvement in conjunction with stage II nodal disease
• Involvement of the liver, bone marrow, lungs, or cerebrospinal fluid
Table 2. 
Ann Arbor staging for Hodgkin lymphoma.
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immunodeficiency syndromes or medical treatment for primary malignancies 
carry an increased risk for developing NHL. Predisposing conditions such as 
ataxia telangiectasia, Nijmegen syndrome, and various mismatch repair diseases 
incur not only increased risk of developing NHL but also increase mortality rates 
from anti-tumor interventions [18]. Immunodeficiency-associated BL is diag-
nosed in patients with Human Immunodeficiency virus (HIV), though the risk of 
tumor development declines with the use of antiretroviral therapy [19–21].
Lymphomas of the head and neck can present insidiously, but are typically discov-
ered as a “rubbery,” enlarged cervical or supraclavicular lymph node on physical exam-
ination. The majority of HL patients present with asymptomatic cervical adenopathy 
with or without the constitutional “B” symptoms including fever, night sweats, chills 
and weight loss which are also incorporated into the HL Ann Arbor staging system. 
While adult NHL is characterized by nodal disease, pediatric NHL has a predisposition 
for extranodal involvement with the most common head and neck extranodal localiza-
tions involving the larynx, sinonasal cavities, salivary glands and orbit. Lymphoma 
is present within Waldeyer’s ring in approximately 44% of cases especially in NHL 
patients [7, 22]. Oguz et al. conducted a retrospective study of 457 pediatric patients 
with lymphadenopathy and demonstrated that chronic lymphadenopathy (greater 
than 4 weeks in duration), generalized and supraclavicular involvement, and lymph 
nodes measuring greater than 3 cm were findings most commonly associated with 
malignancy among 111 patients with confirmed disease [23]. Other causes for concern 
include persistent lymphadenopathy despite antibiosis, nodal firmness, immobility, 
fixation to underlying tissues, and progressive nodal enlargement [7].
Otolaryngologists and other surgeons primarily serve diagnostic roles via lymph 
node biopsy As the initial differential diagnosis for pediatric cervical adenopathy 
is broad and widely varied, a detailed history and physical examination is critical 
to stratify the likelihood of malignancy against other processes such as infection, 
hypersensitivity reactions, granulomatous diseases, and rheumatic or lympho-
proliferative disorders as these patients may present prior to evaluation by other 
clinicians. Prior to surgery, management and workup should include an array of 
laboratory testing which includes complete blood count (CBC) with differential and 
peripheral blood smear, erythrocyte sedimentation rate (ESR), C-reactive protein 
(CRP) level, lactate dehydrogenase (LDH), as well as a serum ferritin, copper and 
alkaline phosphatase levels. Bone marrow biopsy and lumbar puncture (LP) are 
also routinely performed. Imaging should include chest radiograph and ultrasound 
(US) with computed tomography and magnetic resonance imaging (MRI) reserved 
for more suspicious or concerning presentations. Ultrasound is often the imaging 
mainstay given its accessibility without the need for sedation or radiation exposure 
(Table 3); however, CT continues to play an integral role in surveillance because of 
simplicity and rapidity. F-fluorodeoxyglucose positron emission tomography (FDG-
PET) has demonstrated improved sensitivity and specificity in accurately diagnos-
ing lymphoma compared to conventional imaging modalities [24, 25] (Figure 2).
Following imaging, biopsy is needed to obtain a sufficient amount of tissue for 
frozen and permanent histopathologic analysis along with flow cytometry and 
immunohistochemistry as indicated. These specimens should be sent fresh rather 
than in formalin to provide a viable sample responsive to flow cytometry. Following 
diagnosis, staging of disease typically requires bone marrow biopsy and lumbar 
puncture to assess extent of bone marrow involvement and to determine whether 
malignant cells are present in the CSF, respectively. Diagnosis based on fine needle 
aspiration biopsy (FNAB) has remained controversial and challenging as it results 
in a dearth of cellularity from sclerosis, decreased detection of clonal populations, 
and a lack of diagnostic Reed-Sternberg cells [26]. As such, excisional biopsy 
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Necrosis (cystic or 
coagulation), calcifications, 
reticular internal pattern
aHilar (radiating from hilum to cortex), peripheral (flow around cortex); Vascular resistance <0.7 associated with benign process.
bMatting: Blending capsules of adjacent lymph nodes.
Table 3. 
Ultrasound findings of benign versus malignant head and neck lymph nodes.
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Treatment of pediatric lymphoma is non-surgical and includes multi-agent 
chemotherapy with or without radiotherapy (RT) as the first line. With respect 
to the treatment of HL, various combinations of chemotherapeutic agents have 
been utilized with 3- and 8-year event-free survival (EFS) approximating 90% 
and greater than 80%, respectively, while overall survival (OS) has been demon-
strated to range from 80 to 90% [27, 28]. Some regimens include MOPP (mech-
lorethamine, vincristine, procarbazine, prednisone), COPP (cyclophosphamide, 
vincristine, procarbazine, prednisone), and ABVD (adriamycin, bleomycin, 
vinblastine, dacarbazine) [7], each uniquely selected based upon the subtype of 
HL and the side-effect profiles. RT is also commonly added in combination with 
Figure 2. 
Axial CT/PET (A) and axial CT neck with contrast (B) of 10-year-old patient with lymphoblastic lymphoma 
most notable in the left cervical chain. The left jugulodigastric nodes are hypermetabolic (arrowhead) on CT/
PET and enlarged with a hypodense central core with rim-enhancement (arrow) on contrasted CT.
Figure 3. 
(A) Axial CT 1 month status post induction chemotherapy for the same patient noted in Figure 2 with 
lymphoblastic lymphoma. Note residual 1.5 cm node (arrowhead). (B) Axial CT scan of the same patient 
8 months following diagnosis, following completion of chemotherapy. The previously noted adenopathy has 
resolved (arrow) and there is no evidence of recurrence.
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chemotherapy. With NHL, a large number of chemotherapeutic combinations 
are possible, as outlined by Kahn et al.: ABV (doxorubicin, bleomycin, and vin-
blastine), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) 
COPDAC (cyclophosphamide, vincristine, prednisone, and dacarbazine), and 
COPP [29]. In contrast to HL, RT is infrequently used to treat NHL. Additionally, 
if high-grade NHL is present, intrathecal chemotherapy may be indicated. Post-
operative surveillance examinations and imaging are obtained at regular intervals 
to monitor for evidence of disease recurrence (Figure 3).
3. Rhabdomyosarcoma
Rhabdomyosarcoma (RMS), a malignant tumor of mesenchymal origin, is the 
most common pediatric soft tissue sarcoma affecting approximately 250 children 
per year within the United States [30]. It accounts for 4.5% of all childhood malig-
nancies and is the third most common extracranial pediatric solid tumor following 
Wilms’ tumor (nephroblastoma) and neuroblastoma. RMS of childhood is charac-
terized by a bimodal distribution and presents between the ages of 2 and 6 and again 
between 10 and 18 years of age [31]. Although this tumor may arise throughout 
the body given its mesenchymal nature, the head and neck is the most commonly 
involved, comprising 35% of all cases [32–34]. Of the cases involving the head and 
neck, nearly 75% arise within the orbit or parameningeal regions (e.g. nasopharynx, 
nasal cavity, paranasal sinuses, infratemporal fossa, pterygopalatine fossae, and 
middle ear) (Figure 4). The remainder originates primarily in the oral cavity, cheek, 
parotid region and soft tissues of the neck, which are commonly referred to as non-
orbital or non-parameningeal lesions [35, 36]. Although most tumors occur sporadi-
cally, some RMS cases are associated with familial syndromes such as Li Fraumeni 
and neurofibromatosis type I [31, 37, 38]. The tumor typically presents as a painless, 
asymptomatic mass in the majority of cases but may cause compressive symptoms 
and cranial neuropathies secondary to mass effect in more advanced disease.
RMS histology classically appears as a small round blue cell tumor of childhood 
and is classified alongside similar appearing neoplasms including lymphoma, 
Figure 4. 
Embryonal rhabdomyosarcoma. Axial T1 fat-saturated MRI (A) reveals slightly hyper-intense lobular mass of 
the sphenoid wing (star). Axial T2 MRI (B) reveals the same lesion with similar signal intensity (asterisk).
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neuroblastoma, Wilms’ tumor, Ewing’s sarcoma and peripheral neuroectodermal 
tumors. There are two main histologic subtypes of RMS: embryonal (ERMS) and 
alveolar (ARMS). ERMS is the more common subtype and comprises approximately 
75% of cases with a preponderance for younger patients. In contrast, the ARMS 
subtype—appearing histologically similar to pulmonary parenchyma—represents 
approximately 25% of cases and is more prevalent among older children and 
adolescents with the majority occurring in children greater than 10 years of age. 
Compared to ERMS, the ARMS subtype is associated with an unfavorable prog-
nosis. A review of the SEER database performed by Ognjanovic et al. analyzed the 
incidence and survival rates for pediatric and adolescent RMS between 1975 and 
2005 with five-year overall survival rates ranging from 40.1–47.8% and 60.9–73.4% 
for the ARMS and ERMS types, respectively [39]. Similar findings were reported by 
Pappo et al. with five-year survival rates of 97% for non-orbital, non-paramenin-
geal embryonal cases versus 67% for ARMS subtypes [35]. With respect to head and 
neck tumors, the ERMS subtype occurs more frequently and may be further classi-
fied into the botryoid and spindle-cell variants with botryoid histology demonstrat-
ing a more favorable prognosis [34].
Patients with suspected RMS should undergo a thorough workup including a 
complete head and neck physical exam along with laboratory testing, imaging and 
pathologic confirmation prior to treatment. Evaluation for metastatic disease often 
includes a lumbar puncture for cerebrospinal fluid analysis. Imaging studies of the 
primary tumor site often involve CT - which is useful for the evaluation of osseous 
erosion - and MRI for further characterization of the primary tumor and the sur-
rounding anatomy. This is especially beneficial in determining whether the tumor 
may be safely resected with primary surgery or if neoadjuvant treatment is required 
to decrease the morbidity. FDG-PET imaging has so far seen limited use in the 
pediatric population. However, several studies have suggested an increased utility in 
evaluating the presence of lymphadenopathy, occult disease, response to treatment, 
and detection of recurrence compared to standard imaging alone [40–43]. Biopsy is 
required for definitive diagnosis and may often be achieved via fine needle aspiration 
or open biopsy while taking care to obtain an adequate amount of tissue for accurate 
histopathologic analysis. Although lymph node involvement in pediatric head and 
neck RMS is uncommon, determining the presence of locoregional and metastatic 
lymph node involvement is critical in establishing pre-treatment staging and, in cases 
of suspected disease, pathologic evaluation should be undertaken which will further 
influence radiotherapy fields. In an analysis of regional lymph node disease in 898 
patients within the pivotal Intergroup Rhabdomyosarcoma Study IV, Rodeberg and 
colleagues demonstrated that the presence of nodal disease is an independently poor 
prognostic indicator for both failure-free and overall survival, further underlining the 
need to establish the extent of disease prior to treatment [44].
In an effort to design effective and tailored treatment regimens for these 
patients, the Intergroup Rhabdomyosarcoma Study and its subsequent iterations 
(IRS I-IV) established a staging and grouping system to aid in directing treatment 
strategy based upon tumor location, disease extent, and completeness of surgical 
resection [45–48]. Within this classification scheme, the pre-operative “stage” is 
based upon pre-operative standard TNM staging guidelines whereas the post-oper-
ative clinical “group” refers to the extent of disease and completeness of surgical 
resection prior to adjuvant therapy. Group I reflects complete resection with nega-
tive pathologic margins. Group II consists of patients with complete gross resection 
but microscopically positive residual disease (close or positive margins, presence 
of regional nodal disease, or both). Group III includes patients with gross residual 
disease following incomplete resection or unresectable disease. Group IV reflects 
those with distant metastatic disease other than first echelon nodal metastases. 
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An overview of the IRS pre-treatment staging (Tables 4 and 5) and post-treatment 
grouping classification (Table 6) is provided.
Chemotherapy and radiation have remained the mainstay of multimodal treat-
ment for childhood RMS. Recently, there has been an increasing trend towards 
Stage Sites T Tumor 
size
N M
I Orbit T1 or 
T2
a or b N0, N1, or 
Nx
M0
Head and neck (excluding parameningeal) a or b N0, N1, or 
Nx
Genitourinary (non-bladder/non-prostate) a or b N0, N1, or 
Nx
II Bladder/prostate T1 or 
T2
a N0 or Nx M0
Extremity a N0 or Nx
Head and neck (parameningeal) a N0 or Nx
Other (includes trunk, retroperitoneum, etc.) a N0 or Nx
III Bladder/Prostate T1 or 
T2
a N1 M0
Extremity b N0, N1, or 
Nx
Head and neck (parameningeal) b N0, N1, or 
Nx
Other (includes trunk, retroperitoneum, etc.) b N0, N1, or 
Nx
IV All T1 or 
T2
a or b N0 or Nx M1
Table 4. 
TNM pre-treatment staging system for rhabdomyosarcoma.
Classification Description
Tumor
T1 Confined to anatomic site of origin
a <5 cm in diameter
b ≥5 cm in diameter
T2 Extension and/or fixation to surrounding tissue
a <5 cm in diameter
b ≥5 cm in diameter
Regional lymph nodes
N0 Not clinically involved
N1 Clinically involved
Nx Clinical status unknown
Metastases
M0 No distant metastases
M1 Distant metastases present
Table 5. 
Pre-treatment rhabdomyosarcoma TNM classifications.
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primary surgical resection in localized tumors involving the head and neck [49]. 
The success of surgical treatment is often dependent on the specific location of 
tumor [35, 36, 50, 51]. Orbital RMS, associated with a favorable prognosis, is rarely 
associated with meningeal extension and is treated with primary chemotherapy and 
radiation with surgery reserved for salvage cases [52]. On the other hand, parameni-
ngeal lesions are more challenging to remove and are often categorized as IRS Group 
III tumors because they are not typically amenable to complete surgical resection. 
Given its anatomic location in close proximity to vital neurovascular structures, 
parameningeal RMS is associated with an increased likelihood of cranial neuropa-
thies, cranial base erosion, and intracranial extension [53]. As primary surgical 
resection with wide margins is often infeasible for these tumors, chemotherapy with 
or without radiation is the preferred treatment modalities. (Figures 4 and 5). Reilly 
et al. conducted a retrospective chart review of 17 children diagnosed with head and 
neck RMS over an 18-year period and found that the majority presented with cranial 
neuropathies, thus reflecting the aggressive nature of this disease upon symptom 
Figure 5. 
Axial T1 MRI (A) performed 18 months after biopsy, chemotherapy, and proton therapy to treat embryonal 
rhabdomyosarcoma noted in Figure 4 with no evidence of recurrence at the primary site (arrowhead). Axial 
T2 MRI (B) of the same patient at 39 months post-treatment, still with no evidence of recurrence (arrow).
Clinical Group Criteria
Group 1 Localized disease, complete resection, no microscopic residual disease
A Confined to site of origin, complete resection
B Infiltrating beyond site of origin, complete resection
Group 2 Gross total resection
A Gross resection with microscopic residual disease
B Regional disease with spread to regional lymph nodes, complete resection without 
residual microscopic disease
C Regional disease with spread to regional lymph nodes, gross total resection, but evidence 
of microscopic residual disease
Group 3 Incomplete resection or biopsy with gross residual disease remaining
Group 4 Distant metastases present irrespective of surgical approach to tumor
Table 6. 
Post-surgical clinical group staging system for rhabdomyosarcoma.
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onset with 5 of 17 (29.4%) patients demonstrating advanced metastatic disease at 
first referral. Within their series, 4 of 4 patients with non-parameningeal disease 
underwent primary surgical resection but tumor-free margins were unobtainable 
and adjuvant chemotherapy with radiation was ultimately required. All patients with 
parameningeal disease underwent multimodal treatment [54]. However, Daya et al. 
also demonstrated that many children may avoid radiation therapy without compro-
mising survival in cases of completely resected RMS [49].
In general, pediatric RMS necessitates systemic treatment in the form of chemo-
therapy with local control achieved with surgery and/or radiation. The treatment 
approach must nonetheless be carefully tailored for each individual patient accord-
ing to tumor location and the potential morbidities associated with each modality. 
Although primary surgical resection may be possible in select non-parameningeal 
tumors, the decision for adjuvant therapy is ultimately determined by margin status.
4. Thyroid carcinoma
Thyroid carcinoma represents approximately 21% of all pediatric head and neck 
malignancies with an annual reported incidence of 0.54 per 100,000 persons within 
the United States [55, 56]. In contrast to adults, thyroid nodules are less likely to be 
palpable in children (2% vs. 35%) and carry a much higher likelihood of malignancy 
with a risk of 1 in 4 in pediatric patients compared to less than 1 in 10 for adults 
[57]. The majority of thyroid cancers are differentiated with papillary thyroid 
cancer (PTC) accounting for greater than 90% of cases [56]. Less common vari-
ants include follicular thyroid cancer (FTC) and medullary thyroid cancer (MTC) 
while anaplastic and poorly differentiated subtypes are even rarer [58]. MTC is more 
common among younger children (ages 0–4) and declines with increasing age while 
the incidence of PTC increases as one approaches adolescence and adulthood [55]. 
A significant number of patients present with regional lymph node involvement 
(60–80%) and distant metastatic disease may occur in up to 20% of children with the 
lungs most commonly involved [59]. Despite the frequency of advanced disease at 
initial presentation, several case series have demonstrated an excellent prognosis with 
greater than 95% long-term survival for papillary and follicular variants [58, 60–62]. 
Notably, previous radiation exposure and treatment of other childhood malignancies 
increases the risk for developing pediatric thyroid cancer with an 18-fold greater risk 
of thyroid cancer compared to the general population, thus highlighting the impor-
tance of close follow up and frequent surveillance among this cohort [63–65].
The diagnosis of suspected pediatric thyroid cancer involves a focused his-
tory and physical examination with particular attention to previous radiation 
exposure and treatment of prior childhood malignancies, such as lymphoma. 
Patients typically present with an asymptomatic thyroid nodule or mass following 
incidental discovery on surveillance imaging studies. US and FNAB of the most 
suspicious thyroid nodules should be completed along with histocytologic analysis. 
A review of 89 pediatric patients by Buryk et al. examined patients with thyroid 
nodules ≥0.8 cm and demonstrated that larger-sized nodules, palpable nodules, 
and palpable lymphadenopathy were significant predictors of malignancy [66]. 
Sonographic characteristics associated with malignant nodules include larger size, 
solid parenchyma, taller-than-wide shape, microcalcifications, irregular margins, 
and abnormal-appearing lymph nodes [67–69]. Richman et al. also found signifi-
cantly increased rates of cancer in patients with solitary nodules compared to those 
with multiple nodules (29.4% vs. 14.2%, p = 0.003) [69]. Although US is essential 
characterizing thyroid lesions, results may vary according to sonographer skill. 
Neck and chest CT may be useful in evaluating for metastatic disease, cervical 
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lymphadenopathy, and in surgical planning, especially in cases with large-volume 
or bulky disease. Laboratory testing is particularly important and should include 
thyroid-stimulating hormone (TSH), T3, and T4 levels. Serum calcitonin level 
should also be obtained in any patient with known or suspected multiple endocrine 
neoplasia (MEN) syndrome, although routine use remains controversial in patients 
with seemingly isolated MTC [70]. Genetic testing and referral should be consid-
ered in familial cases and in patients with confirmed MTC or MEN syndrome.
Surgical resection is the primary treatment modality for childhood thyroid can-
cer with options including total thyroidectomy and lobectomy with isthmusectomy. 
The American Thyroid Association (ATA) guidelines utilize the American Joint 
Committee on Cancer (AJCC) pTMN staging system to stratify patients into low, 
intermediate, and high-risk groups. Total thyroidectomy is the preferred surgical 
method for PTC given an increased likelihood of bilateral and multifocal disease in 
these tumors [71] (Table 7). The extent of resection nonetheless remains a source 
of controversy. Nice et al. performed a retrospective review of 3861 patients less 
than 21 years old with primary PTC nodule greater than 1 cm in diameter and found 
no significant difference between total thyroidectomy compared to partial thyroid-
ectomy (e.g. sublobar resection, lobectomy, or lobectomy with isthmusectomy) 
on both univariate and multivariate analyses, with both groups demonstrating 
ATA risk level Definitiona Initial post-
operative 
stagingb
Surveillance for pediatric 
patients with no evidence of 
disease
Low Disease grossly confined to the 
thyroid with N0/Nx disease
or
Disease grossly confined to the 
thyroid with N0/Nx disease 
(microscopic metastases to a 
small number of central neck 
lymph nodes)
Tgc US at 6 months postoperatively, 
then annually x 5 years
Tgc on LT4 every 3–6 months x 
2 years, then annually






US at 6 months postoperatively, 
every 6–12 months x 5 years, 
then less frequently
Tgc on LT4 every 3–6 months x 
3 years, then annually
Consider TSH-stimulated 
Tgc ± diagnostic 123I scan in 
1–2 years in patients previously 
treated with 131I
High Regionally extensive disease 
(extensive N1b)
or
Locally invasive disease (T4 






US at 6 months postoperatively, 
every 6–12 months x 5 years, 
then less frequently
Tgc on LT4 every 3–6 months x 
3 years, then annually
Consider TSH-stimulated 
Tgc ± diagnostic 123I scan in 
1–2 years in patients previously 
treated with 131I
aTNM staging from the AJCC Cancer Staging Manual, 7th edition.
bCompleted within 12 weeks following surgery.
cAssumes the absence of thyroglobulin autoantibodies.
LT4, levothyroxine.
Table 7. 
American Thyroid Association (ATA) pediatric thyroid cancer risk classification and post-operative 
management for papillary thyroid carcinoma in children.
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96% 15-year overall survival (OS) [72]. In contrast, Bargen et al. found that, while 
there were no significant increase in surgical complications, patients receiving less 
than total thyroidectomy were at an increased risk for requiring revision surgery 
(p = 0.03) [73]. Despite these differences, outcomes for PTC are excellent with 
long-term survival rates greater than 95% [56, 58, 60–62]. Unlike PTC, FTC is 
more likely to be unifocal and metastasize via hematogenous spread. FTC is com-
monly managed with thyroid lobectomy, but total thyroidectomy with radioactive 
iodine ablation (RAI) is indicated in cases of metastasis, advanced disease, vascular 
invasion, or extracapsular extension. Selective neck dissection, particularly central 
node dissection, is recommended for clinically involved or radiographically abnor-
mal lymph nodes, extrathyroidal tumor extension, and evidence of locoregional 
disease [71]. The utility of neck dissection in the absence of clear clinical indications 
remains poorly defined, but prophylactic neck dissection may be performed in 
patients with advanced disease [74].
MTC is a unique variant of thyroid carcinoma. Most pediatric cases are inherited 
in an autosomal-dominant fashion although sporadic cases are possible. Pediatric 
MTC patients commonly present with bilateral and multifocal thyroid nodules, 
with metastatic disease common at the time of diagnosis. Parafollicular C-cell 
hyperplasia results in an excess production of calcitonin and carcinoembryonic 
antigen (CEA). Mutations in the RET proto-oncogene are responsible for the 
development of the multiple endocrine neoplasia 2 (MEN 2) syndrome which 
is divided into three distinct entities based on the endocrine tissues involved: 
MEN-2A, MEN-2B, and familial MTC [75]. MEN-2A (exons 10 and 11 mutations) 
is characterized by MTC, pheochromocytoma, and primary hyperparathyroidism 
from the presence of parathyroid adenomas. MEN-2B (exon 16 mutations) involves 
MTC, pheochromocytoma, mucosal neuromas (with predisposition for the lips and 
tongue), ganglioneuromas, and marfanoid body habitus. Familial MTC, a variant 
of MEN-2A which accounts for 15% of hereditary MTCs, is characterized by a 
strong familial predisposition to MTC without pheochromocytoma and parathyroid 
adenomas [76, 77]. In suspected cases, thyroid US and FNAB should be performed. 
In addition to thyroid function studies, serum calcitonin and CEA levels should be 
obtained. If concern exists for pheochromocytoma, metanephrine and catechol-
amine testing should be included along with the imaging studies. Genetic testing is 
indicated for children with a familial history of RET mutations and allows for close 
surveillance in these patients prior to the development of disease. Prophylactic total 
thyroidectomy with or without central lymph node dissection is the surgical treat-
ment of choice and may be performed safely in children as early as 5 years of age 
with a family history of germline RET mutations or MEN-2A syndrome [78–80]. For 
those with the MEN-2B syndrome, prophylactic thyroidectomy before age 1 may be 
appropriate, especially if patients are carriers of aggressive codon mutations [81]. 
There is no clear consensus regarding central neck dissection, although this is often 
performed at the time of prophylactic total thyroidectomy [71, 74, 82, 83]. The five-
year OS for MTC is similarly high at approximately 96%, but, the 15- and 30-year 
survival rates are lower at 86% [55].
Following total thyroidectomy, hormone replacement is necessary. Together 
with RAI therapy, it may reduce the risk of tumor recurrence. Long-term surveil-
lance includes serum thyroglobulin levels, thyroid US, and radioiodine-123 (123I) 
diagnostic whole-body scans. Radioiodine-131 (131I) may be used for ablation of 
residual thyroid tissue and is indicated in select pediatric patients with distant 
metastases or residual disease not amenable to surgical resection [71, 84, 85]. 
Complications of RAI are dose-dependent and include pulmonary fibrosis, infertil-
ity, and the development of secondary cancers, thus highlighting the importance of 
careful patient selection as well as follow-up [86].
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5. Nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is a rare pediatric malignancy. Overall, NPC 
accounts for less than 1% of all childhood cancers and represents approximately 
20–50% of nasopharyngeal tumors [87, 88]. Globally, the incidence of pediatric 
NPC is highest throughout southeast Asia, southern China, and the Mediterranean. 
In the United States, childhood NPC is more commonly diagnosed in the southern 
states. The age distribution is bimodal with the first peak in adolescence followed 
by mid-adulthood (ages 40–60) while the distribution in endemic regions (e.g. 
Southeastern Asia and China) is unimodal without a pediatric peak [89]. In all 
regions, the etiology and pathogenesis of NPC is closely related to Epstein–Barr 
virus (EBV) infection with children sharing a closer association with EBV than 
adults [88, 90].
The WHO separates three distinct histopathologic subtypes of NPC: Type I 
(keratinizing squamous cell carcinoma), Type II (non-keratinizing epidermoid 
carcinoma), and Type III (undifferentiated carcinoma) (Table 8) [88, 91]. Type 
I is characterized by the production of keratin, is commonly associated with 
alcohol and tobacco exposure and, as such, is less common in the pediatric popu-
lation. Type I NPC may be found in those with EBV infections in endemic areas. 
Type II and III commonly demonstrate lymphoid, plasmoid, and eosinophilic 
cell infiltration. Type III, also referred to as lymphoepithelioma or Schminke 
tumor, is the most common histopathologic subtype in pediatric patients and 
may be found in as many as 90% of patients with a high rate of distant  
metastases [88].
Childhood NPC most commonly presents a painless neck mass, which may be 
appreciated in 70–90% of patients at the time of first diagnosis. Nasal obstruction, 
epistaxis, and Eustachian tube dysfunction with resultant conductive hearing loss 
and serous otitis media may occur from tumor mass effect [92]. In more advanced 
disease, trismus, headache, facial pain, diplopia with vision changes, and other cra-
nial nerve palsies may be present secondary to skull base involvement [88, 93, 94]. 
Patients with systemic disease may present with paraneoplastic syndromes such as 
syndrome of inappropriate antidiuretic hormone (SIADH) or dermatomyositis [95]. 
Evaluation involves a thorough clinical examination with contrast-enhanced CT and 
MRI with particular attention to skull base structures. Recommended laboratory 
testing includes a CBC, serum chemistry, lactic acid dehydrogenase (LDH) level, 
and liver function panel. More specifically, elevated LDH levels carry prognostic 
significance with higher values shown to correlate with decreased OS, disease-free 
survival (DFS), and distant metastasis-free survival (DMFS) [96, 97]. Bone marrow 
biopsy and CSF cytologic analysis is indicated in cases of distant metastases or when 
skull base extension is suspected while biopsy of the primary tumor is required for 
accurate tissue diagnosis.
Given the rarity of pediatric NPCs, treatment strategies have been tailored from 
established adult guidelines. As these tumors are rarely amenable to surgical resec-
tion, the standard of care for locoregional NPC involves a combination of high-dose 
Type Description
I Keratinizing squamous cell carcinoma
II Non-keratinizing carcinoma
III Undifferentiated carcinoma (Lymphoepithelioma or Schminke tumor)
Table 8. 
World Health Organization (WHO) classification of nasopharyngeal carcinoma.
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radiotherapy (RT) to the primary nasopharyngeal tumor bed and the surrounding 
nodal basin with lower doses targeted at surrounding tissues and uninvolved lymph 
nodes. Due to high rates of locoregional and distant failure in patients presenting 
with advanced disease, chemotherapeutic regimens have recently been incorpo-
rated into treatment schemas. With combined RT and chemotherapy, survival rates 
ranging from 60 to 70% have been reported with some studies documenting as 
high as 90% [89, 90, 94, 98, 99]. In patients with early-stage T1 or T2 disease, single 
modality RT may be utilized. In locally advanced cases, dual modality treatment 
has been shown to result in improved OS compared to RT alone. A meta-analysis 
by Langendijk et al. demonstrated that concurrent chemotherapy was associated 
with a pooled hazard ratio (HR) of 0.48 (95% CI, 0.32–0.72) which corresponded 
to a 20% improvement in five-year OS compared to RT alone while neoadjuvant 
chemotherapy was associated with improved locoregional control with a decreased 
rate of distant metastases [100]. Similar results have been documented throughout 
the literature [101–105]. Despite these advances, many patients continue to present 
with locoregional or systemic recurrence with most relapses occurring within the 
first two years (median 8 months) following treatment [98, 106, 107]. The short 
interval between therapy completion and distant metastases may be a result of 
occult disease at the time of presentation. Notably, T and N classification, total 
irradiation dose, presence of metastatic disease at diagnosis, and delay in time to 
RT have all been demonstrated as prognostic factors in locoregional control of 
NPC [93, 105–110].
6. Salivary gland malignancy
Pediatric salivary gland malignancies are rare and comprise approximately 3% of 
head and neck cancers in the pediatric population and 5% of salivary gland malig-
nancies overall [111]. In contrast to adults, the majority of salivary gland neoplasms 
in children are malignant in nature (40–60%) and most are epithelial in origin. The 
parotid gland is the most common site and mucoepidermoid carcinoma (MEC) 
represents the vast majority of salivary gland malignancies. Less common histologic 
subtypes include acinic cell carcinoma (24–40%) and adenoid cystic carcinoma 
(15–26%) [112]. Several series have evaluated treatment outcomes associated with 
these tumors and demonstrate surgical resection as the mainstay of treatment 
followed by adjuvant RT in select instances [112–119]. A retrospective study by 
Ribeiro and colleagues reviewed outcomes associated with the treatment of 38 
pediatric patients with salivary gland neoplasms, 27 (71.1%) of whom presented with 
malignant tumors [116]. MEC was the most frequent pathology occurring in 17 of 27 
(69.3%) cases followed by 3 patients with adenoid cystic carcinoma; the remaining 
seven patients had a diverse range of rare malignancies. The parotid gland was the 
most common primary site followed by minor salivary glands and submandibular 
gland with 74.1%, 22.2%, and 7.4% of the cases, respectively. All were treated with 
surgical resection while 10 patients underwent concurrent neck dissection; however, 
only 6 were found to have pathologically positive lymph node disease. RT was admin-
istered to a total of 10 patients (neoadjuvant in 2 patients, adjuvant in 8 patients) and 
chemotherapy in 3 individuals. Overall, five and ten-year survival rates were both 
81.6% with tumor differentiation found to be a significant prognostic factor in those 
with MEC with a five-year OS of 100% in low-grade histology compared to 50% 
for intermediate and high-grade histology (p = 0.01). Similar findings have been 
reported throughout the literature [118–121]. Despite the limited sample size in these 
series, the results highlight the central role of surgery in these patients with favorable 
long-term outcomes and facial nerve preservation. Moreover, while adjuvant therapy 
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is utilized in select cases, no standard criteria has been agreed upon likely owing to 
the relative rarity of these tumors. The decision to pursue RT and chemotherapy 
varies between institutions with some centers advocating its use in high-grade 
histology and in the presence of aggressive histological features such as perineural or 
intravascular invasion; however, soft-tissue extension and multi-level lymph node 
involvement are findings which more commonly result in its use [118, 119].
While MEC is the most common adult and childhood malignant salivary gland 
tumor, it has also been reported to occur more frequently in patients previously 
treated with RT and/or chemotherapy regimens for both cancerous and benign 
pathology [122–124]. A literature review by Verma et al. assessed the characteristics 
and treatment outcomes of 58 patients selected from 23 studies with treatment-
related MEC and showed a significantly shorter latent time to the development of 
MEC from initial treatment in those treated with chemotherapy with or without RT 
compared to RT alone (7.9 years vs. 27.2 years) [120]. The primary MEC treatment 
modality was surgery alone in the majority of patients (64.9%) or in combination 
with radiation (29.8%) while the remaining patients received surgery plus che-
motherapy, or underwent RT alone. Survival was similar to those documented in 
previous studies with two and five-year OS rates of 98.0% and 93.4%, respectively. 
Despite favorable survival, the potential for the development of secondary malig-
nancy underscores the importance of continued surveillance in these patients for 
not only salivary gland cancers but other solid tumor malignancies (Table 1).
Clinically, most salivary gland neoplasms present as asymptomatic masses and 
are rarely associated with cranial neuropathies; the presence of facial nerve weak-
ness or other cranial nerve deficits should heighten the suspicion for malignant 
potential [111, 112, 125, 126]. US remains the first-line imaging modality and has 
been shown to be useful in combination with FNAB in establishing a timely diag-
nosis, specifically in parotid tumors [127]. While CT is useful for further imaging 
characterization, MRI is superior in demonstrating soft-tissue enhancement 
which is particularly beneficial in evaluating the status of the facial nerve, lingual 
nerve, and other surrounding neurovascular structures [128]. Open biopsy should 
be avoided given the potential for injury to the facial nerve, especially in children 
with parotid tumors, and possibility for tumor seeding [129, 130]. Treatment 
consists of local excision with tumor-free margins of the affected salivary gland. 
In the case of partial or total parotidectomy, careful attention to preserving 
facial nerve function is recommended as the critical neurovascular structures 
are smaller in pediatric patients. The same principles hold true in cases of sub-
mandibular gland malignancy where the marginal mandibular and lingual nerve 
should be preserved [112, 131]. A review of the SEER database from 1973 to 2006 
by Sultan et al. identified a total of 263 children and adolescents with salivary 
gland carcinoma and, in comparison to adults, found that disease is more often 
localized (50%) with regional lymph node metastases being less common (11% vs. 
31%) [117]. The need for neck dissection in children is poorly understood as the 
majority of tumors are low-grade without occult nodal disease. As a result, several 
authors have suggested that neck dissection be performed in cases of clinically 
evident nodal involvement and high-grade histology which may altogether avoid 
the need for adjuvant therapy in the absence of positive margins or pathologically 
positive nodal disease [116, 125, 132, 133].
7. Osteosarcoma
Sarcomas account for 14% of primary head and neck malignancies in children 
and adolescents. Osteosarcoma remains the most common subtype consisting of 
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approximately 0.5% of the cases and Ewing sarcoma is the second most common 
cancer of bone [1]. Osteosarcoma most frequently involves the long bones of the 
extremities (e.g. distal femur, proximal tibia, proximal humerus) but may occur 
in the mandible or maxilla which are the most commonly involved head and neck 
subsites [134–139]. In general, childhood mandibular and maxillary tumors are 
benign and are discovered incidentally during routine dental examinations or 
non-related imaging studies [140, 141]. Head and neck osteosarcoma is also associ-
ated with a better prognosis when compared to their long bone counterparts with 
three and five-year survival rate at approximately 65% [142–144]. Patients tend to 
present during adolescence with a painless mandibular mass, but pain, edema, loose 
dentition, paresthesias, diplopia, or cranial nerve palsies are especially suspicious 
for malignancy [134, 135, 144].
Management and treatment protocols are primarily based upon large trials or 
meta-analyses focused on osteosarcoma of the limbs and trunk [145]. In addition 
to laboratory studies, imaging commonly involves a combination of plain radio-
graphs, CT, MRI, and 99 m technetium methylene disphosphonate bone scans 
[146–148]. The classic “sunburst” finding in addition to a “fluffy” or spiculated 
osseous appearance suggests the presence of an aggressive periosteal reaction 
along with osteolytic or osteoblastic bony destruction associated with malignancy. 
Lesions are sampled for histologic determination of subtype which includes the 
osteoblastic, chondroblastic, and fibroblastic high-grade forms with tumor grade 
carrying prognostic significance [137, 149–152]. Estimating survival rates for 
pediatric head and neck osteosarcoma is difficult as studies tend to group adult 
and pediatric patients together. Despite this, surgical resection appears to play an 
important role with negative surgical margins being the most important prognostic 
factor [142, 143, 153–157]. Similar to other surgically resected tumors, adjuvant RT 
and chemotherapy are reserved for use in cases with incompletely resected disease 
or in the setting of positive surgical margins. In the case of unresectable disease, 
RT and chemotherapy either as single or multi-modal therapy may be indicated, 
Figure 6. 
Monophasic synovial sarcoma. (A) Post-contrast axial T1 MRI demonstrating a T4aN0M0 monophasic 
synovial cell sarcoma of the right infratemporal fossa and parapharyngeal space in a 15-year-old male (star). 
Post-contrast axial T1 fat suppressed MRI (B) status-post composite resection demonstrating a right segmental 
mandibulectomy and resection of tumor involving the infratemporal fossa, parapharyngeal space, and 
pterygoid base. A total parotidectomy with facial nerve preservation and right selective neck dissection (levels 
I-IV) was also performed. The 1-month postoperative fibula free flap is visualized (asterisk).
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though RT should be approached with particular care as some studies attribute RT 
as a causative intervention for OS. Other less common sarcomas exist (e.g., fibrosar-
coma, synovial cell sarcoma, chondrosarcoma, liposarcoma), although a complete 
discussion of the management of these entities is outside the scope of this review. 
Nonetheless, surgical resection remains the mainstay of treatment in many of these 
diagnoses and leads to a successful outcome when complete resection with tumor-
free margins is obtained (Figure 6).
8. Conclusion
Pediatric head and neck malignancies represent a minority of childhood tumors. 
Although the relative rarity of these tumors largely prevents initiation of high-
volume trials, experiences from adult cases and in pediatric case reports stipulate 
that multimodal therapy is often indicated based upon the specific histopathology, 
stage, and anatomic sites involved. In select instances, primary surgical manage-
ment with or without free tissue transfer and microvascular reconstruction may 
also be indicated. While adjuvant therapy including post-operative radiation 
may improve long-term survival rates, careful consideration must be given to the 
potential for the development of deleterious side effects in young children including 
secondary malignancies later in life.
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